Fangzhou Inc. (06086.HK), a prominent Internet healthcare solution provider in China, was the only digital health innovator invited to the Modern Industrial System Development Summit, which was hosted by the Guangzhou Industrial Development Research Institute on April 1, 2025. This exclusive forum brought together executives from leading companies like Alibaba and Baidu, as well as representatives from academia and government agencies, to discuss strategies for establishing Guangzhou as a national leader in domain-specific large language AI models. These models are considered a crucial element of China's "new quality productive forces."

Dr. Xie Fangmin, the founder, chairman, and CEO of Fangzhou, emphasized the company's commitment to advancing domain-specific AI models. According to Dr. Fangmin, Fangzhou is dedicated to creating AI solutions that address real-world healthcare challenges while upholding the highest standards of safety and efficacy.

A key highlight of Fangzhou's presentation at the summit was the unveiling of its comprehensive safety architecture designed to ensure the accuracy and reliability of medical AI. Recognizing the potential risks associated with AI in healthcare, such as flawed symptom assessments or the dissemination of false drug information, Fangzhou has developed a three-tiered safety system. This innovative framework leverages a combination of a robust knowledge database, multi-model collaboration, and stringent safety controls. The aim is to minimize hallucinations (inaccurate or nonsensical outputs) and mitigate risks by ensuring the integrity of data sources, optimizing model training processes, and rigorously validating the outputs generated by the AI models.

Fangzhou also presented a blueprint for vertical AI leadership, proposing a two-tiered approach to accelerate Guangzhou's development of expertise in domain-specific AI. On the research and development front, the company recommended strengthening interdisciplinary talent development in medical AI, fostering the creation of high-impact use cases, and accelerating the commercialization of these technologies. For industry deployment, the proposed strategy focuses on bolstering infrastructure, emphasizing practical applications, and fostering ecosystems, with targeted support for specialized and innovative companies.

Fangzhou's expansion plans are closely linked to its implementation of advanced AI models, such as DeepSeek-V3, and strategic collaborations with Tencent Health and Tencent Cloud. These partnerships aim to advance the development of AI-enabled healthcare solutions. The company intends to enhance its technological capabilities and accelerate the commercialization of its innovations, with the ultimate goal of providing improved experiences for both patients and users.

Fangzhou Inc. (06086.HK) is recognized as China's leading online chronic disease management platform, serving a vast user base of 49.2 million registered users and 223,000 physicians as of December 31, 2024. The company specializes in delivering tailored medical care and precision medicine solutions. The Modern Industrial System Development Summit aims to establish Guangzhou as a hub for strategic sectors like AI and biotech by 2025. Vertical-specific models are prioritized under China's 2024 State Council AI guidelines to counter "homogeneous competition" in generic AI.